Print Page  Close Window    

Investor Relations Home

Corporate Profile

La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases.

Featured Documents

06/16/18A Phase 1, Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of LJPC-401
06/16/18EHA Poster
12/22/17GIAPREZA™ (angiotensin II) Update

Share Price

Stock chart for: LJPC.OQ.  Currently trading at $30.44 with a 52 week high of $41.24 and a 52 week low of $22.68.
Price$30.44
Change (%) Stock is Down 0.56 (1.81%)
Volume99,354
Data as of 06/15/18 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.


Upcoming Events




There are currently no events scheduled.

Recent News


La Jolla Pharmaceutical Company Announces LJPC-401 Presentations at 23rd Congress of the European Hematology Association

05/17/18

SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More

La Jolla Pharmaceutical Company Announces $125 Million Royalty Financing Agreement with HealthCare Royalty Partners

05/10/18

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC) (La Jolla), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffer

Read More

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress

05/10/18

SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from li

Read More